Nykredit A/S’s Acadia Pharmaceuticals ACAD Stock Holding History

Nykredit A/S’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.5K	Buy	+1,521	New	+$33.5K	﹤0.01%	1551

Other funds holding ACAD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Nykredit A/S's ACAD Position: Q2 2026 in Review

Nykredit A/S opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 1,521 shares worth $38.5K. The stake represents ﹤0.01% of the portfolio and ranks #1551 among its holdings.

248 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Nykredit A/S held 1,521 shares of Acadia Pharmaceuticals worth $38.5K as of Q2 2026.
Acadia Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
Acadia Pharmaceuticals made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1551 holding.
248 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.